CompletedPhase 2NCT02911116
Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
Studying Intermediate uveitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Eye Institute (NEI)
- Principal Investigator
- Hatice N Sen, M.D.National Eye Institute (NEI)
- Intervention
- Ustekinumab(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2020
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02911116 on ClinicalTrials.gov